ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.96

Change

-0.02 (-0.76)%

Market Cap

USD 0.07B

Volume

0.03M

Analyst Target

USD 7.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.01 (-0.06%)

USD 1.64B
RCUS Arcus Biosciences Inc

+0.03 (+0.31%)

USD 0.91B
NUVB Nuvation Bio Inc

+0.03 (+1.22%)

USD 0.77B
DNA Ginkgo Bioworks Holdings

-0.33 (-4.37%)

USD 0.41B
CYBN Cybin Inc

+0.24 (+2.80%)

USD 0.15B
ADCT ADC Therapeutics SA

+0.10 (+2.99%)

USD 0.14B
PLX Protalix Biotherapeutics Inc

-0.08 (-5.00%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.03 (-1.81%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

-0.07 (-2.86%)

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

-0.02 (-1.17%)

USD 0.05B

ETFs Containing ARMP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.95% 77% C+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.95% 77% C+ 75% C
Trailing 12 Months  
Capital Gain -23.74% 67% D+ 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.74% 67% D+ 10% F
Trailing 5 Years  
Capital Gain -48.96% 67% D+ 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.96% 67% D+ 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -0.13% 63% D 36% F
Dividend Return -0.13% 60% D- 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.35% 66% D+ 14% F
Risk Adjusted Return -0.25% 60% D- 25% F
Market Capitalization 0.07B 69% C- 22% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.